| Dr Randall Lundgren, DC | |
|
662 S Ferguson Ave Ste 1, Bozeman, MT 59718 | |
| (406) 586-1984 | |
| (406) 551-2049 |
| Full Name | Dr Randall Lundgren |
|---|---|
| Gender | Male |
| Speciality | Chiropractic |
| Experience | 32 Years |
| Location | 662 S Ferguson Ave Ste 1, Bozeman, Montana |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1861572224 | NPI | - | NPPES |
| M011000443 | Other | MT | MEDICARE PTAN |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 111NX0800X | Chiropractor - Orthopedic | 708 (Montana) | Primary |
| Provider Name | Lundgren Chiropractic Clinic |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1336454305 PECOS PAC ID: 7416145768 Enrollment ID: O20101230000614 |
News Archive
According to a new study, an antidepressant prescribed over the last 13 years is ineffective and potentially harmful. The drug in question is called Reboxetine and is available under the name of Edronax. The study showed that it works no better than a placebo.
Bayer HealthCare Pharmaceuticals announced today that an orphan drug designation has been granted by the U.S. Food and Drug Administration for ciprofloxacin dry powder inhaler for management of pulmonary infection due to Pseudomonas aeruginosa in cystic fibrosis patients. A similar designation has already been granted by the European Medicines Agency.
Nektar Therapeutics reported partner AstraZeneca today announced that MOVENTIG (naloxegol) has been granted Marketing Authorisation by the European Commission for the treatment of opioid-induced constipation (OIC) in adult patients who have had an inadequate response to laxative(s).
Taking a pill that prevents the accumulation of toxic molecules in the brain might someday help prevent or delay Alzheimer's disease, according to scientists at Baylor College of Medicine, Texas Children's Hospital and Johns Hopkins University School of Medicine.
Janssen Research & Development, LLC (JRD) announced today that the U.S. Food and Drug Administration (FDA) has assigned a Priority Review designation to the supplemental New Drug Application (sNDA) filed on December 29, 2011 for XARELTO (rivaroxaban), an oral anticoagulant, to reduce the risk of thrombotic cardiovascular events in patients with Acute Coronary Syndrome (ACS).
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Randall Lundgren, DC 662 S Ferguson Ave Ste 1, Bozeman, MT 59718-6492 Ph: (406) 586-1984 | Dr Randall Lundgren, DC 662 S Ferguson Ave Ste 1, Bozeman, MT 59718 Ph: (406) 586-1984 |
News Archive
According to a new study, an antidepressant prescribed over the last 13 years is ineffective and potentially harmful. The drug in question is called Reboxetine and is available under the name of Edronax. The study showed that it works no better than a placebo.
Bayer HealthCare Pharmaceuticals announced today that an orphan drug designation has been granted by the U.S. Food and Drug Administration for ciprofloxacin dry powder inhaler for management of pulmonary infection due to Pseudomonas aeruginosa in cystic fibrosis patients. A similar designation has already been granted by the European Medicines Agency.
Nektar Therapeutics reported partner AstraZeneca today announced that MOVENTIG (naloxegol) has been granted Marketing Authorisation by the European Commission for the treatment of opioid-induced constipation (OIC) in adult patients who have had an inadequate response to laxative(s).
Taking a pill that prevents the accumulation of toxic molecules in the brain might someday help prevent or delay Alzheimer's disease, according to scientists at Baylor College of Medicine, Texas Children's Hospital and Johns Hopkins University School of Medicine.
Janssen Research & Development, LLC (JRD) announced today that the U.S. Food and Drug Administration (FDA) has assigned a Priority Review designation to the supplemental New Drug Application (sNDA) filed on December 29, 2011 for XARELTO (rivaroxaban), an oral anticoagulant, to reduce the risk of thrombotic cardiovascular events in patients with Acute Coronary Syndrome (ACS).
› Verified 2 days ago
Bozeman Family Chiropractic Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 1351 Stoneridge Dr, Suite B, Bozeman, MT 59718 Phone: 406-586-5252 Fax: 406-586-5454 | |
Active Family Chiropractic & Rehab Chiropractor Medicare: Medicare Enrolled Practice Location: 1925 N 22nd Ave, Suite 103, Bozeman, MT 59718 Phone: 406-556-0307 Fax: 406-556-0310 | |
Mr. Wade Anthony Darr, DC Chiropractor Medicare: Accepting Medicare Assignments Practice Location: 2616 W Main St Ste B, Bozeman, MT 59718 Phone: 406-586-5810 Fax: 406-586-5583 | |
Crux Sports Chiropractic & Injury, Llc Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 1528 W Main St, Bozeman, MT 59715 Phone: 406-612-1253 Fax: 406-262-8887 | |
Elite Chiropractic Limited Liability Company Chiropractor Medicare: Medicare Enrolled Practice Location: 2245 W Koch St, Suite A, Bozeman, MT 59718 Phone: 406-587-0711 | |
Dr. Erik Morrell, DC Chiropractor Medicare: Accepting Medicare Assignments Practice Location: 2405 W Main St Ste 8, Bozeman, MT 59718 Phone: 406-219-2462 | |
406 Chiropractic, Pllc Chiropractor Medicare: Medicare Enrolled Practice Location: 1045 Reeves Rd E, Ste C, Bozeman, MT 59718 Phone: 406-848-1275 |